What Are the Pros and Cons of Prenatal Screening Tests?

Prenatal screening tests give expectant parents early information about whether a pregnancy is at increased risk for chromosomal conditions like Down syndrome, structural abnormalities like spina bifida, and certain inherited genetic disorders. The main advantages are early awareness, time to prepare, and the ability to plan medical care before or immediately after birth. The main disadvantages are the possibility of false-positive results that trigger unnecessary anxiety and invasive follow-up procedures, the emotional weight of uncertain or alarming findings, and the gap between what the tests can flag and what they can definitively prove. Understanding those trade-offs matters because prenatal screening has become routine in many countries, and parents are often offered these tests without fully grasping what the results can and cannot tell them.

What Prenatal Screening Can Tell You

Screening tests are not the same as diagnostic tests. A screening test estimates probability. It tells you whether a pregnancy is at higher or lower risk for specific conditions. A diagnostic test tells you, with near-certainty, whether the condition is actually present. Most parents first encounter screening, not diagnosis, and the distinction is critical for interpreting results correctly.

The most common screening approaches fall into a few categories. First-trimester combined screening uses a blood draw and an ultrasound measurement of the fluid at the back of the fetus’s neck (nuchal translucency) to estimate the risk of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Cell-free DNA screening, often called NIPT, analyzes fragments of placental DNA circulating in the pregnant person’s blood and can flag the same trisomies plus sex chromosome differences. The mid-pregnancy anatomy scan, typically done around 18 to 20 weeks, looks for structural abnormalities in the brain, heart, spine, kidneys, and limbs. Separately, expanded carrier screening checks whether one or both parents carry gene variants linked to hundreds of recessive disorders, from cystic fibrosis to sickle cell disease.

The key advantage shared by all these approaches is time. A screening result returned at 10 or 12 weeks gives parents months to seek genetic counseling, pursue confirmatory testing, prepare emotionally, arrange specialist care at delivery, or consider pregnancy management options. For certain structural conditions detected on ultrasound, prenatal diagnosis can open the door to fetal surgery. Conditions such as spina bifida, urinary tract obstruction, diaphragmatic hernia, and twin-to-twin transfusion syndrome have shown improved outcomes after in-utero intervention.¹

How Accurate Is Cell-Free DNA Screening

NIPT has become the headline screening method because its accuracy numbers look impressive on paper. A large meta-analysis found pooled sensitivity of about 99% for Down syndrome, around 97% for Edwards syndrome, and around 97% for Patau syndrome, with specificity above 99.9% for all three.² Those numbers are genuinely better than older serum-and-ultrasound screening, which had higher false-positive rates.

But there is a well-documented gap between what those percentages mean in a clinical study and what they mean for an individual person holding a positive result. Sensitivity and specificity describe how the test performs across a population. What you actually want to know when your result comes back “high risk” is the positive predictive value: how likely is it that this result is correct for my pregnancy? That number depends heavily on how common the condition is in your age group and risk category. For a 25-year-old with no other risk factors, the chance that a positive NIPT result for Down syndrome is a true positive can be substantially lower than for a 40-year-old, even though the test’s sensitivity is the same for both. Marketing materials sometimes obscure this by advertising sensitivity and specificity above 99%, which many patients and even some clinicians misread as near-diagnostic certainty.³

The screening also works less reliably for rarer conditions. When NIPT is expanded beyond the common trisomies to screen for microdeletions like 22q11.2 (DiGeorge syndrome), the positive predictive value drops further because those conditions are so uncommon that even a very specific test generates more false alarms than true detections in an unselected population.⁴

Why False Positives Happen

The biology behind false positives is worth understanding because it explains why even a highly accurate test can mislead. NIPT does not actually test the fetus directly. It reads DNA fragments shed by the placenta into the pregnant person’s bloodstream. If the placenta and the fetus have different chromosomal makeups, a situation called confined placental mosaicism, the test may call a result abnormal when the fetus itself is fine. Research confirms that confined placental mosaicism is a frequent contributor to false-positive cell-free DNA results, particularly for monosomy X and rare autosomal trisomies.⁵

Placental mosaicism is not the only source of error. A vanishing twin, where an early co-twin with a chromosomal abnormality stops developing but still sheds DNA, can trigger a high-risk result for the surviving fetus. Maternal factors can also interfere: uterine fibroids, unrecognized chromosomal mosaicism in the parent, and even undiagnosed maternal cancers have been documented as causes of false positives.⁶ When genome-wide NIPT returns complex results involving multiple chromosomes, research has found that about 40% of those cases were ultimately linked to a maternal malignancy, most often breast cancer or lymphoma.⁷ Maternal genomic variants also remain a significant and largely unsolved source of false positives for microdeletion screening.⁸

None of this means NIPT is unreliable. It means it is a screening tool, not a diagnosis, and every positive result needs to be confirmed by amniocentesis or chorionic villus sampling before any irreversible decision is made.

What Confirmatory Testing Involves

When screening flags a high-risk result, the next step is usually an invasive diagnostic procedure: amniocentesis (a needle through the abdomen to sample amniotic fluid, typically after 15 weeks) or chorionic villus sampling, known as CVS (a needle or catheter to sample placental tissue, typically between 10 and 13 weeks). Both provide a direct look at the fetus’s chromosomes and are considered definitive.

The trade-off is physical risk. The question every parent asks is: could this test cause a miscarriage? The numbers have improved over the decades as techniques have refined, but the risk is not zero. A large systematic review and meta-analysis found a procedure-related miscarriage risk of roughly 0.3% for amniocentesis and about 0.2% for CVS, though when the comparison group was matched for similar baseline risk, the added risk from the procedure itself became smaller still and in some analyses was not statistically distinguishable from zero.⁹ A national registry study from Taiwan reported a miscarriage rate of about 0.7% after midtrimester amniocentesis, which was roughly 0.2% higher than in those who did not undergo the procedure.¹⁰

For many parents, a false-positive screening result thus sets off a chain reaction: abnormal screen, referral for counseling, decision about whether to undergo an invasive procedure with a small but real risk, then a wait of days or weeks for diagnostic results. Even when the final answer is reassuring, the experience is not trivial.

The Emotional Cost of Screening

One of the most consistently documented downsides of prenatal screening is the psychological toll of false-positive results. Research going back decades has shown that receiving an abnormal screening result is associated with high levels of anxiety, increased worry about the baby’s health, and a more negative attitude toward the pregnancy.¹¹ A systematic review of seven studies found that false-positive results cause an immediate spike in psychological distress, primarily manifesting as heightened anxiety and stress in expectant mothers and, to a lesser extent, fathers.¹²

The anxiety is not always short-lived. A study comparing Icelandic women who received false-positive first-trimester screening results with those who received true negatives found that self-reported anxiety levels were significantly higher in the false-positive group at the time of the result, and for some women that anxiety persisted through the rest of the pregnancy or even beyond it.¹³ This lingering worry can color the entire experience of pregnancy, even after diagnostic testing has confirmed the fetus is healthy.

True-positive results carry their own emotional complexity, of course, but the point about false positives is that the distress is, in a sense, iatrogenic: it was created by the test itself, in a pregnancy that was fine all along. This is the core tension in screening. You cannot identify the pregnancies that need attention without also alarming some that do not.

Nuchal Translucency and Ultrasound Findings

While NIPT dominates discussions about screening accuracy, ultrasound-based markers remain an important part of the picture. A thickened nuchal translucency measurement in the first trimester can signal chromosomal problems, but it also picks up structural heart defects and single-gene disorders that NIPT does not screen for at all. A recent meta-analysis of fetuses with nuchal translucency between 3.0 and 3.4 mm found chromosomal anomalies in about 13% of cases, with Down syndrome accounting for the largest share. Interestingly, single-gene disorders identified through further genetic sequencing were found in nearly 6% of these cases.¹⁴

This highlights a practical advantage of ultrasound screening that sometimes gets lost in the enthusiasm for blood-based tests. A detailed anatomy scan can detect physical abnormalities, from heart defects to neural tube problems, that no amount of DNA analysis in the blood will reveal. The two approaches are complementary, and relying on NIPT alone would miss a meaningful slice of detectable conditions.

Carrier Screening Is a Different Conversation

Expanded carrier screening deserves its own mention because it answers a fundamentally different question. Rather than asking “does this fetus have a chromosomal condition?” it asks “do the parents carry hidden gene variants that could combine to cause a recessive disorder in their child?” Expanded carrier screening can now cover hundreds of conditions in a single test panel.¹⁵

The carrier rates are higher than most people expect. A study of over 2,500 people in China found that roughly 39% carried at least one disease-causing variant, and about 4% of couples screened were identified as at-risk pairs for the same recessive condition.¹⁶ A separate study of over 3,000 individuals in southern China found an even higher overall carrier frequency of about 62%, with nearly a quarter carrying variants for more than one condition.¹⁷

The advantage of this information is straightforward: at-risk couples can pursue preimplantation genetic testing with IVF, prenatal diagnosis early in pregnancy, or simply be prepared for the possibility that their child may be affected. The downside is that carrier status for a recessive condition does not mean your child will be affected. Even when both parents carry the same variant, the chance of an affected child in any given pregnancy is typically one in four. The sheer volume of results from a panel covering hundreds of conditions can generate confusion and anxiety, especially without good genetic counseling to contextualize what the numbers mean.

The “Just Another Blood Test” Problem

One of the more subtle risks of modern prenatal screening is that it has become too easy. NIPT requires only a single blood draw. There is no physical discomfort, no waiting room ultrasound jelly, nothing that signals to the patient that they are making a consequential medical decision. Ethicists and researchers have flagged that many pregnant people treat NIPT as routine, accepting it automatically without fully considering what they would do with an abnormal result.¹⁸

This matters because an unexpected high-risk result can be deeply destabilizing when someone never paused to think about it as a possibility. The argument from ethicists is not that screening should be harder to access, but that pre-test counseling should focus less on explaining the technical details of the test and more on helping people make a personal, value-consistent decision about whether they want this information at all. Research into decision aids, educational videos, and structured counseling sessions has shown that these interventions can improve informed decision-making, though integrating them into routine clinical workflows remains a challenge.¹⁹

Insurance, Cost, and Who Gets Access

The benefits of prenatal screening are unevenly distributed. A study at a quaternary medical center found that uninsured or self-pay patients were significantly less likely to receive genetic counseling and aneuploidy screening compared to those with public or private insurance.²⁰ But having insurance does not guarantee coverage either. Across the United States, many private insurers do not cover initial NIPT for people classified as low-risk, creating a financial barrier that effectively limits who gets to choose the most sensitive available screening option. One study found that women with public insurance were more than three times as likely to have NIPT as their first aneuploidy screen compared to women with private insurance, because Medicaid in some states covered it while private plans did not.²¹

The result is a patchwork where access depends less on medical need than on what kind of insurance card you carry and what state you live in. NIPT can cost several hundred dollars out of pocket when not covered, which is not a trivial expense for many families. This raises a fairness question: if screening is recommended for all pregnancies, it should be accessible to all pregnancies.

Commercial Pressures and Marketing

The rollout of NIPT was driven in large part by commercial laboratories competing for market share, and this has shaped how the tests are presented to both clinicians and patients. An analysis of industry marketing materials found that NIPT brochures frequently misrepresented screening tests as diagnostic, made claims without supporting evidence, and invoked regulatory bodies that do not actually evaluate the test’s clinical validity.²² In countries without state-sponsored screening programs, multiple commercial NIPT products covering a wide and sometimes poorly validated range of conditions are available directly to consumers, with limited regulatory oversight.²³

The practical consequence for parents is that you may be offered an expanded panel that screens for microdeletions and rare conditions with substantially lower positive predictive values than the core trisomy screen. The marketing may not make this distinction clear. Asking your provider specifically what conditions the test covers, what the expected false-positive rate is for each, and whether expanding the panel actually changes your medical management is a reasonable form of self-advocacy.

Disability, Autonomy, and the Bigger Ethical Questions

Prenatal screening for conditions like Down syndrome inevitably intersects with how society values people living with those conditions. Disability rights advocates have long raised concern that widespread screening implicitly sends a message that certain lives are less worth living. A survey of the U.S. public found that regardless of personal opinions about disability, a majority of respondents supported both the availability of screening and the decision to continue a pregnancy that screened positive for aneuploidy.²⁴ People rationalized their support with varying and sometimes contradictory conceptions of disability, reflecting that this is genuinely contested moral territory rather than a question with a clean answer.

There is also a legal dimension. In some jurisdictions, failure to inform a patient about the availability of NIPT, or misinterpretation of results, could lead to a “wrongful birth” claim if a child is born with a detectable condition. Research suggests that liability concerns influence how physicians recommend screening, potentially pushing more clinicians toward blanket recommendation rather than individualized counseling.²⁵ The worry is that this dynamic turns screening from a choice into a default, eroding the autonomy it is supposed to serve.

Where the Technology Is Heading

The inherent limitation of current NIPT is that it reads placental DNA, not fetal DNA directly. A small number of intact fetal cells do circulate in the pregnant person’s blood, and isolating those cells could theoretically allow a full diagnostic-level genetic analysis from a simple blood draw, combining the safety of a screening test with the accuracy of amniocentesis.²⁶ Recent work using automated cell-sorting technology has shown progress in isolating these rare cells efficiently enough for high-throughput clinical use.²⁷

If this technology matures, it could eliminate the biggest practical trade-off in prenatal testing: the choice between a safe-but-imperfect screen and an accurate-but-invasive diagnosis. That would not resolve the ethical, emotional, and access questions, but it would remove the physical risk that currently sits at the center of the decision-making process for millions of families each year.